BioCentury on BioBusiness,
Analyst Picks & Changes
Analyst picks & changes
Published on
Monday, December 3, 2012
|
Company
|
Bank
|
Analyst
|
Coverage
|
Opinion
|
Wk
chg
|
11/30
cls
|
|
Acadia
Pharmaceuticals Inc. (NASDAQ:ACAD)
|
Needham
|
Alan
Carr
|
Upgrade
|
Buy
(from hold)
|
134%
|
$5.20
|
|
Carr
also set a $9 target after Acadia reported that once-daily 40 mg oral pimavanserin
as an adjunct to stable doses of existing anti-Parkinson's therapy met the
primary endpoint in the Phase III ACP-103-020 trial to treat Parkinson's
disease psychosis (PDP) (see B24). Acadia is planning an identical
Phase III trial, but did not provide a timeline. Pimavanserin is a small
molecule serotonin (5-HT2A) receptor inverse agonist.
|
|
Bruker
Corp. (NASDAQ:BRKR)
|
Goldman
Sachs
|
Isaac
Ro
|
Upgrade
|
Buy
(from neutral)
|
0%
|
$14.60
|
|
Ro
raised his target to $19 from $13 on better-than-expected organic growth for
the tool supply company. Bruker reported revenue of $447.8M and an EPS of
$0.28 for 3Q12, beating the Street's estimates of $421.4M in revenue and an
EPS of $0.15. Ro said the company is re-aligning its presence away from
Europe into emerging markets, where long-term trends remain very favorable.
He models 7% organic top-line growth for 2013-15 compared with about 5% for
other tool companies. Bruker was up 7% for the week ended Nov. 23, when Ro
issued his report.
|
195
words displayed of
715
words total.
To read this article, you must be an Archives subscriber. Please choose one of the options below.
All contents Copyright © 1993-2013 BioCentury Publications, Inc. ALL RIGHTS RESERVED. All use of this Web Site and its contents is governed by the BioCentury User Agreement and the BioCentury Terms of Use. The contents of this Web Site are protected under U.S. and foreign copyright and intellectual property laws, and no part of this Web Site or its contents may be photocopied, reproduced or retransmitted in any form without the written consent of BioCentury, which may be requested from Reprints/Permissions at www.biocentury.com. BioCentury®; The Bernstein Report on BioBusiness™; The BioCentury 100™; The Clear Route to ROI™; Because Real Intelligence is Hard to Find™; BCIQ™; and BioPharma's Knowledge Center™; are trademarks of BioCentury Publications, Inc., P.O. Box 1246, San Carlos, CA 94070. SciBX® and SciBX: Science-Business eXchange® are trademarks of Nature America, Inc. that are jointly used by BioCentury Publications, Inc. and Nature America, Inc.
|
Current Subscribers
If you are a current subscriber, log in below or in the upper right corner of this
page.
Log In
Subscription Option
Whether you want an individual subscription or need a global group license, we have the products,
the experience and the customer support that biopharma executives, researchers, investors, service providers,
and industry stakeholders have trusted for nearly two decades.
Let our Subscriber Services team customize the best intelligence package available in the industry to meet your needs.
Free Trial 4 Weeks of Access
Get a 4-week free trial subscription to see the important articles you are missing.
Get 4 Weeks Free
Thank You
Thanks for purchasing this article.
Please bookmark this url for future reference.
We have also sent you a confirming e-mail with a receipt and this same url for your
records.
close [ X ]